Interim Report January-March 2008 Tripep AB (publ)

Interim Report January-March 2008 Tripep AB (publ)

•	Research and development costs amounted to SEK 6.6 (3.4) million
•	The loss after tax was SEK -9.9 (-6.5) million
•	Earnings per share were SEK -0.16 (-0.12)
•	The company had no net sales for the period
•	Rights issue completed
•	Patent application filed for a new antibiotic-free formulation of ChronSeal in
collaboration with Kringle Pharma, Inc.
•	Application filed with the Swedish Medical Products Agency for a phase II
trial on ChronSeal
•	Safety study on ChronSeal concluded successfully - good efficacy in acute
wounds suggesting extended indication
•	More information required before Tripep's phase II trial on ChronSeal can
begin
•	Tripep secured a first US patent on a new type of immunotherapy against HIV-1
•	Preliminary positive results in the first patient in the current ChronVac-C®
study




For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail:
jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .